Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
UVB Capital is a venture capital firm based in Salt Lake City, Utah, focused on building and investing in next-generation life science companies. Founded to collaborate with entrepreneurs in the healthcare sector, UVB Capital emphasizes a hands-on approach to support innovative solutions across various diseases and modalities. The firm operates with a stage-agnostic investment strategy, targeting opportunities from pre-seed to Series C.
Currently, UVB Capital's investment strategy encompasses a wide range of life sciences sectors, including biotechnology and pharmaceuticals. The firm is committed to driving positive patient outcomes through its investments and actively engages with portfolio companies to enhance their operational efficiency and innovation capabilities. Although specific details about the firm's assets under management (AUM) and fund size are not disclosed, UVB Capital's focus on impactful healthcare solutions positions it as a significant player in the life sciences investment space.
UVB Capital adopts a stage-agnostic investment strategy, focusing on the life sciences sector. The firm invests across all stages, from pre-seed to Series C, with initial check sizes ranging from $500,000 to $20 million. This flexibility allows UVB Capital to engage with a diverse array of companies, from early-stage startups to more established firms seeking growth capital.
The firm specifically targets opportunities that align with its mission to foster innovation in healthcare and therapeutics. UVB Capital considers a broad spectrum of diseases and modalities, ensuring that its investment portfolio reflects the dynamic nature of the life sciences field. The firm seeks to partner with entrepreneurs who are committed to developing solutions that can significantly impact patient care and health outcomes.
UVB Capital's portfolio includes several notable companies in the life sciences sector:
The investment status of these companies has not been fully disclosed, but their focus areas align with UVB Capital's mission to support impactful healthcare innovations.
David Bearss — Partner at UVB Capital, David Bearss is also the CEO and co-founder of Halia Therapeutics. He has extensive experience in drug development and has previously served as CEO of Tolero Pharmaceuticals.
Greg Bokar — Another key member of the UVB team, Greg Bokar has a background as former EVP, General Counsel, and Corporate Secretary at Sunovion Pharmaceuticals. His expertise includes legal, governance, IP, compliance, and M&A.
Marc Hansen — A cell biologist with a PhD from Stanford, Marc Hansen has a strong academic background and experience as a biotech founder. He is recognized for his contributions to cancer biology and life sciences.
Keith Marmer — As Managing Partner, Keith Marmer co-founded UVB Capital in January 2023. He also serves as President at Seek Labs and Chief Business Officer at Biolexis Therapeutics, bringing valuable operational experience to the firm.
To pitch UVB Capital, founders should use the email address Info@uvbcapital.com or visit their website at uvbcapital.com. The firm does not specify a formal pitch form, allowing for flexibility in how pitches are presented. Founders are encouraged to include key information about their business model, market opportunity, and team in their pitch materials.
While the firm maintains an open pitch policy, it is advisable for founders to be concise and clear in their communications. Response times may vary, so patience is recommended after submitting a pitch.
In July 2024, UVB Capital was mentioned in a press release regarding Halia Therapeutics, highlighting the firm's involvement in the life sciences sector. The firm continues to focus on building and investing in next-generation life science companies, with ongoing efforts to support innovative healthcare solutions.
As of May 2026, UVB Capital remains active in the venture capital space, with a commitment to fostering innovation in healthcare and therapeutics. The firm is positioned to engage with emerging life sciences companies and contribute to advancements in patient care.
What are UVB Capital's investment criteria?
UVB Capital invests in the life sciences sector, focusing on companies at various stages from pre-seed to Series C. The firm looks for innovative solutions across a wide range of diseases and modalities.
How can I pitch to UVB Capital?
Founders can pitch to UVB Capital by sending an email to Info@uvbcapital.com or visiting their website at uvbcapital.com. The firm maintains an open pitch policy.
What makes UVB Capital different from other investors?
UVB Capital emphasizes a hands-on approach, leveraging the expertise of its team to support portfolio companies in achieving capital efficiency and impactful healthcare innovations.
What is the geographic focus of UVB Capital?
The firm primarily invests in the United States, with a specific emphasis on opportunities within Utah.
What is the typical check size for investments?
UVB Capital typically invests between $500,000 and $20 million in its portfolio companies, depending on the stage and needs of the business.
What kind of support can portfolio companies expect?
UVB Capital provides operational expertise, access to extensive networks, and a commitment to hands-on company building, helping portfolio companies navigate challenges and drive growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.